pursuing the following strategies:•Complete clinical development and seek marketing approvals for ataluren for the treatment of nmDMD and nmCF.•Commercialize ataluren through our own focused, specialized sales force initially in the European Union and the United
companies in which you hold stock.7Table of ContentsThe offeringCommon stock offered by us$100,000,000 of shares of our common stock.Common stock to be outstanding after this offering29,172,451 sharesOver-allotment optionThe underwriters have an option for a period of 30 days to purchase up to $15,000,000 of additional shares of our common stock to cover over-allotments.Use of proceedsWe intend to use the net proceeds from this offering to fund the clinical development of and seek marketing approval for ataluren for the treatment of nmDMD, to fund the clinical development of and
results for any interim period are not necessarily indicative of results to be expected for a full fiscal year.Year endedDecember 31,Nine months endedSeptember 30,Statement of operations data(in thousands, except share and per share data)2011201220122013Revenues:Collaboration revenue$98,961$28,779$22,861$27,395Grant revenue6,4515,1674,4452,890Total revenues105,41233,94627,30630,285Operating expenses:Research and development58,67746,13936,68939,855General and administrative16,15314,61511,39117,735Total operating expenses74,83060,75448,08057,590Income (loss) from operations30,582(26,808)(20,774)(27,305)Interest income (expense), net(2,444)(1,210)(1,007)(6,250)Loss on extinguishment of debt———(130)Other income, net4611,7831,818(3)Income (loss) before tax benefit28,599(26,235)(19,963)(33,688)Income tax benefit2,306———Net income (loss)30,905(26,235)(19,963)(33,688)Deemed dividend———(18,249)Gain on exchange of convertible preferred stock in connection with recapitalization—159,954159,9543,391Less beneficial conversion charge—(378)(378)—Net income (loss) attributable to common stockholders$30,905$133,341$139,613$(48,546)Net income (loss) per share(1)Basic$23.95$219.76$182.41$(5.40)Diluted$4.55$42.50$39.41$(5.40)Weighted-average shares outstanding:Basic1,0893,3282,9378,995,167Diluted5,72917,20513,5938,995,167(1)    See
Note 8 to our audited financial statements appearing at the end of this prospectus regarding the calculation of net income per share.10Table of ContentsSeptember 30, 2013Balance sheet data(in thousands)ActualAs adjusted(1)Cash, cash equivalents and marketable securities$157,227$250,677Working capital146,217239,667Total assets167,244260,694Long-term debt, including current portion8484Convertible preferred stock——Accumulated deficit(310,912)(310,912)Total stockholders' equity (deficit)151,033244,483(1)    The as adjusted balance sheet gives effect to our issuance and sale of $100.0 million of shares of our common stock in this offering at an
anticipate that our expenses will increase substantially in connection with initiating and completing confirmatory Phase 3 clinical trials for our lead product candidate, ataluren, for the
plans, we do not expect to generate significant revenue unless and until we obtain marketing approval for, and commercialize, ataluren for the treatment of nmDMD or nmCF.
successful in a range of challenging activities, including:•obtaining approval to market ataluren for the treatment of either or both of nmDMD and nmCF;•successfully initiating and completing confirmatory Phase 3 clinical trials of ataluren for the treatment of either
In addition, if we obtain regulatory approval for ataluren or any of our other product candidates, we expect to incur significant commercialization expenses related to product
conditional approval to market ataluren in the European Union prior to completion of confirmatory Phase 3 clinical trials;•establishing commercial manufacturing arrangements with third-party manufacturers;•building an infrastructure capable of supporting product sales, marketing and distribution of ataluren in territories
need to conduct more than one confirmatory clinical trial and our ability to receive marketing approval for this indication could be delayed or prevented.Because we are developing product candidates for the treatment of diseases in which there is little clinical experience and, in some cases, using new endpoints or
delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of the company to decline and limit our ability to obtain
significant delays or may require us to abandon one or more clinical trials altogether.If serious adverse or inappropriate side effects are identified during the development of ataluren or any other product candidate, we may need to abandon or limit our
including:•the efficacy and potential advantages compared to alternative treatments;•the prevalence and severity of any side effects;•the ability to offer our product candidates for sale at competitive prices;21Table of Contents•convenience and ease of administration compared to alternative treatments;•the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;•the strength of marketing and distribution support;•sufficient third-party coverage or reimbursement; and•any restrictions on concomitant use of other medications, such as a restriction that nmCF patients taking ataluren not
trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to or necessary for our programs.Even if we are able to commercialize ataluren or any other product candidate that we develop, the product may become subject to unfavorable pricing regulations, third-party
The market price for our common stock may be influenced by many factors, including:•the success of competitive products or technologies;•results of clinical trials of ataluren and any other product candidate that we develop;•results of clinical trials of product candidates of our competitors;•regulatory or legal developments in the United States and other countries;•developments or disputes concerning patent applications, issued patents or other proprietary rights;•the recruitment or departure of key personnel;•the level of expenses related to any of our product candidates or clinical development programs;•actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities
fibrosis caused by nonsense mutations;•our plans to pursue research and development of other product candidates;•the potential advantages of ataluren;•the rate and degree of market acceptance and clinical utility of ataluren;•our estimates regarding the potential market opportunity for ataluren;•our sales, marketing and distribution capabilities and strategy;•our ability to establish and maintain arrangements for manufacture of ataluren and our other product candidates;•our intellectual property position;•our expectations related to the use of proceeds from this offering;•our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;•the impact of government laws and regulations;•our competitive position; and•our expectations with respect to development and regulatory status of our program directed against spinal muscular atrophy
things, that we do not receive conditional approval to market ataluren for nmDMD or nmCF prior to completing a Phase 3 clinical trial for the applicable indication and, as a result, that we do
additional indications and for our other product candidates;•the number and development requirements of other product candidates that we pursue;•the costs, timing and outcome of regulatory review of ataluren and our other product candidates;•the costs and timing of commercialization activities, including product sales, marketing, distribution and manufacturing,
additional indications and for our other product candidates;•the number and development requirements of other product candidates that we pursue;•the costs, timing and outcome of regulatory review of ataluren and our other product candidates;•the costs and timing of commercialization activities, including product sales, marketing, distribution and manufacturing,